ストックスクリーナーアプリを入手
0.00
100.00%
-8.61
前日終値:
$8.61
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$391.22M
収益：
$84.82M
当期純損益:
$-21.43M
株価収益率:
0.00
EPS:
-0.49
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$11.10
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
名前
Y Mabs Therapeutics Inc
セクター
電話
646-885-8505
住所
202 CARNEGIE CENTER, PRINCETON, NY
YMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
0.00 | 391.22M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-11-18 | 開始されました | Oppenheimer | Outperform |
| 2024-08-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 開始されました | Truist | Buy |
| 2023-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-04-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-27 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-12-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-10-31 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-10-31 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 再開されました | Guggenheim | Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-11-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-23 | 再開されました | Cowen | Outperform |
| 2021-03-22 | 再開されました | JP Morgan | Overweight |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2020-05-01 | 開始されました | Janney | Buy |
| 2020-04-29 | 開始されました | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 開始されました | JP Morgan | Overweight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-04 | 開始されました | Wedbush | Outperform |
| 2019-04-01 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-10-16 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Why Y mAbs Therapeutics Inc. stock is a must watch in 2025Swing Trade & Real-Time Buy Zone Alerts - moha.gov.vn
The Technical Signals Behind (YMAB) That Institutions Follow - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. stock attractive for ETFsPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Is Y mAbs Therapeutics Inc. stock trading at a premium valuationGap Down & Weekly Watchlist for Hot Stocks - newser.com
United States Brain Cancer Treatment Market in 2025 | Novel Drug - openPR.com
Why Y mAbs Therapeutics Inc. stock is considered a top pickEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Can Y mAbs Therapeutics Inc. stock withstand economic slowdownQuarterly Growth Report & Technical Buy Zone Confirmations - newser.com
Can Y mAbs Therapeutics Inc. stock continue upward trendDividend Hike & AI Optimized Trading Strategy Guides - newser.com
What’s next for Y mAbs Therapeutics Inc. stock priceQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
How strong is Y mAbs Therapeutics Inc. stock balance sheet2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Is it too late to sell Y mAbs Therapeutics Inc.Market Activity Summary & Consistent Income Trade Recommendations - newser.com
Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical Officer - GlobeNewswire
Is Y mAbs Therapeutics Inc. stock a dividend growth opportunityWeekly Profit Summary & Verified Entry Point Detection - newser.com
Does Y mAbs Therapeutics Inc. stock trade at a discount to peersM&A Rumor & Safe Entry Zone Identification - newser.com
Institutional scanner results for Y mAbs Therapeutics Inc.July 2025 Trends & Stepwise Trade Signal Implementation - newser.com
How Y mAbs Therapeutics Inc. stock trades before earningsMarket Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Y mAbs Therapeutics Inc. stock a buy on dipsWeekly Gains Report & Verified Entry Point Detection - Fundação Cultural do Pará
Why analysts upgrade Y mAbs Therapeutics Inc. stockGap Up & Safe Entry Trade Signal Reports - newser.com
How geopolitical tensions affect Y mAbs Therapeutics Inc. stockJuly 2025 Patterns & Reliable Momentum Entry Alerts - newser.com
Precision Trading with Y-mabs Therapeutics Inc. (YMAB) Risk Zones - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. stock reversal real or fake2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
How supply chain issues affect Y mAbs Therapeutics Inc. stock2025 Fundamental Recap & Capital Protection Trading Alerts - newser.com
How to forecast Y mAbs Therapeutics Inc. trends using time seriesTrade Performance Summary & Weekly High Potential Alerts - newser.com
Analyzing net buyer seller activity in Y mAbs Therapeutics Inc.July 2025 Momentum & Weekly Market Pulse Alerts - newser.com
Y Mabs Therapeutics Inc (YMAB) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):